Today we have even more bad news in two separate studies about the diabetes drug Avandia. With the bad news we get all the time about diabetes you might wonder why I report more negative stuff.
Steve Nissen has a way of getting everybody’s attention. And he does that with tools that in anybody else’s hands would be deadly dull. This week he captured the attention of one of the country’s most prestigious medical journals, the Food and Drug Administration, U.S. senators and members of Congress, our leading newspapers, Wall Street, class-action lawyers, and last, but hardly least millions of people who have diabetes.